Search Results
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la aprobación de una indicación adicional para MINJUVI® (tafasitamab) en Brasil
(tafasitamab)MINJUVI® (tafasitamab) (tafasitamab) es un anticuerpo monoclonal citolítico humanizado con modificaciones en la región Fc dirigido a CD19. Tafasitamab incorpora un dominio Fc de ingeniería XmAb®, que media la lisis de células B a través de la apoptosis y mecanismos efectores
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 06:00 ET Introducing Chainguard Actions: Trusted CI/CD Workflows for Developers and AI Coding Agents
The most privileged and least protected layer in the CI/CD pipelineCI/CD workflows operate with the highest privileges in modern software delivery, yet they remain among the least protected components in the development
More news about: Chainguard
Mar 17, 2026, 06:00 ET Chainguard Introduces the Guardener: Intelligent, Continuous Maintenance for Secure Software Artifacts
secure-by-default open source software accessible to developers to automate migrations, dependency updates, and ongoing artifact maintenance directly within their CI/CD environments.
More news about: Chainguard
Mar 17, 2026, 06:00 ET Chainguard Launches the First Unified Repository for Secure-by-Default Open Source Artifacts
One experience for every container, library, OS package, virtual machine, CI/CD workflow,and agent skill that developers and AI agents consume, with security that improvesautomatically as Chainguard builds more artifacts from sourceKIRKLAND,
More news about: Chainguard
Mar 17, 2026, 05:49 ET IIT Roorkee Inaugurates Ashok Soota Molecular Medicine Facility at BSBE to Advance Translational Biomedical Research
GC-MS, Iso-Thermal Calorimeter (ITC), Flow Cytometer, Upright Confocal Microscope, Small-Angle X-ray Scattering (SAXS), Protein Crystallization Robot, CD Spectrometer, High Pressure Homogenizer/Cell Disruptor, and other high-precision analytical platforms. This comprehensive infrastructure significantly
More news about: SKAN Research Trust
Mar 16, 2026, 17:00 ET LangChain Announces Enterprise Agentic AI Platform Built with NVIDIA
comprehensive evaluation across the full agent lifecycle. LangSmith supports offline evaluation (human review, LLM-as-judge, pairwise comparison, CI/CD integration via pytest/Vitest/GitHub workflows) and online evaluation including multi-turn evals that score entire conversation trajectories for task
More news about: LangChain
Mar 16, 2026, 10:01 ET Neuromyelitis Optica Spectrum Disorder Market Poised for Robust Expansion Through 2036 | DelveInsight
CD40/CD40L Inhibitors MarketCD40/CD40L Inhibitors Market, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CD40/CD40L inhibitors
More news about: DelveInsight Business Research, LLP
Mar 16, 2026, 08:30 ET How to Accelerate Innovation with PCCPs and CI/CD for Medical Devices, Upcoming Webinar Hosted by Xtalks
speakers will discuss how to automate testing, validate and release workflows by integrating PCCPs with continuous integration and continuous delivery (CI/CD). The speakers will also share how to operationalize continuous validation with real-world data, model performance tracking and drift monitoring. Attendees
More news about: Xtalks
Mar 16, 2026, 02:00 ET Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
https://pubmed.ncbi.nlm.nih.gov/36449413/ - Accessed in March 2026[9] Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023;330(6):512-527. doi:10.1001/jama.2023.13239.
More news about: Roche
Mar 16, 2026, 02:00 ET Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
https://pubmed.ncbi.nlm.nih.gov/36449413/ - Accessed in March 2026[9] Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023;330(6):512-527. doi:10.1001/jama.2023.13239.
More news about: Roche
Mar 15, 2026, 22:05 ET Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
the "molecular brakes" on remaining myeloid populations by ILT2 and ILT4 blockade. Meanwhile, ILT2 blockade by AK150 also has the potential to activate CD8+ T cells and Natural Killer (NK) cells, enhancing the anti-tumor immune response. This innovative design holds promise for addressing key challenges
More news about: Akeso, Inc.
Mar 13, 2026, 06:23 ET AI-HealthTech Innovator Humata Health Partners with AccuKnox for Zero Trust CNAPP
Management (ASPM) capabilities - including full Azure DevOps and GitLab integration - Humata Health gains unified visibility and control across its CI/CD pipeline.""This win showcases how alignment, agility, and customer-first execution drive real outcomes," said Emre Kulali, VP of Strategic Partnerships,
More news about: AccuKnox
Mar 12, 2026, 09:58 ET Former Chief Security Officer at Meta, Uber, and Cloudflare Joins StackHawk Board to Help Security Teams Keep Pace with AI
entirely to what happens when code runs. StackHawk is the only company I've seen that tests applications the way attackers exploit them: dynamically, in CI/CD, before production. That's the approach that makes sense in 2026."
More news about: StackHawk
Mar 11, 2026, 07:06 ET ActiveState Appoints Open Source and Technology Leader, Abby Kearns, to CEO to Drive Next Phase of Growth
provides a trusted catalog of more than 79 million secure open source components and container images that can be consumed via artifact repository, CI/CD, IDE, or directly from ActiveState. ActiveState continuously monitors and updates the open source components to help keep companies vulnerability free.
More news about: ActiveState
Mar 10, 2026, 17:31 ET CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
othersScope of the CD-19 Inhibitors Market ReportCD-19 Inhibitors Therapeutic Assessment: CD-19 Inhibitors' current marketed and emerging therapiesCD-19 Inhibitors Market Dynamics: Conjoint Analysis of Emerging CD-19 Inhibitors DrugsCompetitive
More news about: DelveInsight Business Research, LLP
Mar 10, 2026, 13:00 ET Renue By Science Wins Precision Recovery & Performance Award at the 2026 INNOCOS Wellness & Longevity CHOICE Awards
distinct biological pathways: boosting NAD+ production with multiple precursors (NMN, NR, NAD+, and trigonelline), protecting against NAD+ loss from CD38 enzyme activity, optimizing mitochondrial efficiency, and supporting deep cellular repair during sleep.The protocol includes four coordinated
More news about: Renue By Science
Mar 10, 2026, 09:07 ET March 2026 CD Rate Trends: CD Valet Finds Community Institutions Offering CD Returns Almost One Percentage Point Higher Than Big National Banks
environment."About CD ValetCD Valet is a CD marketplace that features verified CD rates from federally insured banks and credit unions. With tens of thousands of CD offers tracked across the country, CD Valet gives savers a clear view of top rates and helps them explore high-yield CD options with
More news about: CD Valet
Mar 10, 2026, 09:03 ET Opsera Unveils AppSec AI Agents to Power the Shift from traditional SDLC to AI-SDLC
Agentic DevOps platform acts as the control plane for AI-SDLC, coordinating specialized AI agents across security, compliance, architecture, and CI/CD workflows. By automating pre-commit validation and continuous enforcement, Opsera enables organizations to:Reduce security vulnerabilities
More news about: Catapult PR-IR
Mar 10, 2026, 08:48 ET Allstacks Launches Agent to Close the Spec Gap Limiting AI-Assisted Development
in October 2025. Both operate on a shared context graph - a normalized data layer that maps relationships across project management, source control, CI/CD, and quality systems. Delivery risk tells leaders which initiatives are in trouble and what to do about it; spec readiness identifies and corrects specification
More news about: Allstacks
Mar 10, 2026, 08:30 ET Azilen Technologies Delivers 2.7x Capital Velocity Using Agentic AI in Lending Across Underwriting & Credit Operations
first-pass approval consistency.Engineering rigor supported the deployment. Infrastructure-as-code frameworks eliminated configuration drift, while CI/CD pipelines enforced automated testing, security scans, and dependency audits prior to release. Reusable agent frameworks, version-controlled model interfaces,
More news about: Azilen Technologies
Mar 10, 2026, 08:13 ET Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
Mice Treated with GDNFProtein expression analysis showed:No change in PPARγ expressionNo change in CD36 expressionThese proteins are associated with hepatic lipid uptake and fat accumulation, indicating that GDNF improved metabolic
More news about: Hoth Therapeutics, Inc.
Mar 10, 2026, 07:30 ET ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit.Zemcelpro® (dorocubicel) has recently received conditional marketing
More news about: ExCellThera
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit.Zemcelpro® (dorocubicel) has recently received conditional marketing
More news about: ExCellThera
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) : des résultats positifs dans les cancers du sang à haut et très haut risque seront présentés lors du congrès annuel 2026 de l'EBMT
nouveau produit cryoconservé de greffe de cellules souches hématopoïétiques comprenant deux composants, à savoir des cellules CD34+ expansées par UM171 (dorocubicel) et des cellules CD34- non expansées, chacune provenant de la même unité de sang de cordon.Zemcelpro® (dorocubicel) qui est développé
More news about: ExCellThera